These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6412349)

  • 1. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.
    Catoggio LJ; Skinner RP; Maddison PJ
    Rheumatol Int; 1983; 3(1):19-21. PubMed ID: 6412349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of anti-centromere antibodies. Clinical value].
    Meyer O; Haim T; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):261-6. PubMed ID: 6348931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.
    Chorzelski TP; Jablonska S; Beutner EH; Blaszczyk M; Jarzabek-Chorzelska M; Kencka D; Krasny S; Kumar V; Tchórzewska A
    Br J Dermatol; 1985 Oct; 113(4):381-9. PubMed ID: 3877519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 7. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
    Fritzler MJ; Kinsella TD
    Am J Med; 1980 Oct; 69(4):520-6. PubMed ID: 6968511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scl 70 antibody--a specific marker of systemic sclerosis.
    Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
    Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.
    Aeschlimann A; Meyer O; Bourgeois P; Haim T; Belmatoug N; Palazzo E; Kahn MF
    Ann Rheum Dis; 1989 Dec; 48(12):992-7. PubMed ID: 2515813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticentromere antibodies. Diagnostic and prognostic value].
    Meyer O; Haïm T
    Nouv Presse Med; 1982 Oct; 11(39):2891-4. PubMed ID: 6755388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticentromere antibody--clinical associations. A study of 44 patients.
    Caramaschi P; Biasi D; Manzo T; Carletto A; Poli F; Bambara LM
    Rheumatol Int; 1995; 14(6):253-5. PubMed ID: 7597381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease.
    Goldman JA
    Ann Rheum Dis; 1989 Sep; 48(9):771-5. PubMed ID: 2802800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term longitudinal study of anticentromere antibodies.
    Tramposch HD; Smith CD; Senecal JL; Rothfield N
    Arthritis Rheum; 1984 Feb; 27(2):121-4. PubMed ID: 6607733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of patients with anticentromere antibody.
    Takehara K; Soma Y; Igarashi A; Kikuchi K; Tamaki T; Ishibashi Y
    Dermatologica; 1990; 181(3):202-6. PubMed ID: 2135387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological markers in progressive systemic sclerosis: clinical correlations.
    Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
    Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive systemic scleroderma. Diagnostic and prognostic significance].
    Meurer M; Scharf A; Luderschmidt C; Braun-Falco O
    Dtsch Med Wochenschr; 1985 Jan; 110(1):8-14. PubMed ID: 3880700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antinuclear, anticentromere and anti-ScL-70 antibodies in rheumatic diseases].
    Ivanova SM; Melkumova KL; Il'in KV; Riazantseva TA; Piven' VA; Speranskiĭ AI
    Lab Delo; 1990; (6):50-3. PubMed ID: 1699041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dysimmune rheumatism in Raynaud's syndrome (inflammatory rheumatism, Raynaud's syndrome, speckled antinuclear factors and anti-ribonucleoprotein antibody): a new syndrome?].
    Appelboom T; Kahn MF; Peltier AP; de SEZE S
    Ann Med Interne (Paris); 1974 Nov; 125(11):841-8. PubMed ID: 4218716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.